Therapeutic Advances in Drug Safety-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2196208, encodeId=33b8219620862, content=1月份投的，马上4月份了，给编辑发了邮件还是没有回审稿意见, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06608356051, createdName=ms4000000341726267, createdTime=Sat Mar 30 11:29:44 CST 2024, time=2024-03-30, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2177807, encodeId=5e5f21e780779, content=投稿发表时间：普遍一审一个月，二审一个月，总历时2-3个月接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54111233, createdTime=Thu Dec 28 15:51:58 CST 2023, time=2023-12-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2179053, encodeId=2d3e21e905393, content=投了一篇，投稿发表流程还是可以的，一审二审基本差不多都是一个月左右的等待，给了一些反馈和建议整个发表过程在2-3个月的时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a7d6407081, createdName=ms358551321, createdTime=Wed Jan 03 15:51:56 CST 2024, time=2024-01-03, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2178721, encodeId=7c9921e8721be, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：该期刊发表的研究可信度和质量都很高，影响因子在过去一年内好像增长了36%，自引率一直比较低4.4%左右，很厉害, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0af16407062, createdName=ms31231444, createdTime=Tue Jan 02 09:41:09 CST 2024, time=2024-01-02, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2176598, encodeId=fbaf21e65988b, content=仔细研究了一下这本期刊，在药学领域的知名度还是很高的，在JCR评估中还获得了Q2的排名。是个潜力骨。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Fri Dec 22 20:24:21 CST 2023, time=2023-12-22, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1113505, encodeId=d3801113505c3, content=两个IF相当的期刊，如何选择要投哪个？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:55 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113506, encodeId=124f111350676, content=选刊时有什么原则吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Tue Dec 28 14:52:55 CST 2021, time=2021-12-28, status=1, ipAttribution=)]

2024-03-30 ms4000000341726267 来自湖北省

1月份投的，马上4月份了，给编辑发了邮件还是没有回审稿意见

3 0

[GetPortalCommentsPageByObjectIdResponse(id=2196208, encodeId=33b8219620862, content=1月份投的，马上4月份了，给编辑发了邮件还是没有回审稿意见, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06608356051, createdName=ms4000000341726267, createdTime=Sat Mar 30 11:29:44 CST 2024, time=2024-03-30, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2177807, encodeId=5e5f21e780779, content=投稿发表时间：普遍一审一个月，二审一个月，总历时2-3个月接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54111233, createdTime=Thu Dec 28 15:51:58 CST 2023, time=2023-12-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2179053, encodeId=2d3e21e905393, content=投了一篇，投稿发表流程还是可以的，一审二审基本差不多都是一个月左右的等待，给了一些反馈和建议整个发表过程在2-3个月的时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a7d6407081, createdName=ms358551321, createdTime=Wed Jan 03 15:51:56 CST 2024, time=2024-01-03, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2178721, encodeId=7c9921e8721be, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：该期刊发表的研究可信度和质量都很高，影响因子在过去一年内好像增长了36%，自引率一直比较低4.4%左右，很厉害, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0af16407062, createdName=ms31231444, createdTime=Tue Jan 02 09:41:09 CST 2024, time=2024-01-02, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2176598, encodeId=fbaf21e65988b, content=仔细研究了一下这本期刊，在药学领域的知名度还是很高的，在JCR评估中还获得了Q2的排名。是个潜力骨。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Fri Dec 22 20:24:21 CST 2023, time=2023-12-22, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1113505, encodeId=d3801113505c3, content=两个IF相当的期刊，如何选择要投哪个？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:55 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113506, encodeId=124f111350676, content=选刊时有什么原则吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Tue Dec 28 14:52:55 CST 2021, time=2021-12-28, status=1, ipAttribution=)]

2023-12-28 MS54111233 来自上海

投稿发表时间：普遍一审一个月，二审一个月，总历时2-3个月接收。

16 0

[GetPortalCommentsPageByObjectIdResponse(id=2196208, encodeId=33b8219620862, content=1月份投的，马上4月份了，给编辑发了邮件还是没有回审稿意见, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06608356051, createdName=ms4000000341726267, createdTime=Sat Mar 30 11:29:44 CST 2024, time=2024-03-30, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2177807, encodeId=5e5f21e780779, content=投稿发表时间：普遍一审一个月，二审一个月，总历时2-3个月接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54111233, createdTime=Thu Dec 28 15:51:58 CST 2023, time=2023-12-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2179053, encodeId=2d3e21e905393, content=投了一篇，投稿发表流程还是可以的，一审二审基本差不多都是一个月左右的等待，给了一些反馈和建议整个发表过程在2-3个月的时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a7d6407081, createdName=ms358551321, createdTime=Wed Jan 03 15:51:56 CST 2024, time=2024-01-03, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2178721, encodeId=7c9921e8721be, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：该期刊发表的研究可信度和质量都很高，影响因子在过去一年内好像增长了36%，自引率一直比较低4.4%左右，很厉害, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0af16407062, createdName=ms31231444, createdTime=Tue Jan 02 09:41:09 CST 2024, time=2024-01-02, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2176598, encodeId=fbaf21e65988b, content=仔细研究了一下这本期刊，在药学领域的知名度还是很高的，在JCR评估中还获得了Q2的排名。是个潜力骨。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Fri Dec 22 20:24:21 CST 2023, time=2023-12-22, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1113505, encodeId=d3801113505c3, content=两个IF相当的期刊，如何选择要投哪个？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:55 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113506, encodeId=124f111350676, content=选刊时有什么原则吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Tue Dec 28 14:52:55 CST 2021, time=2021-12-28, status=1, ipAttribution=)]

2024-01-03 ms358551321 来自上海

投了一篇，投稿发表流程还是可以的，一审二审基本差不多都是一个月左右的等待，给了一些反馈和建议整个发表过程在2-3个月的时间

19 0

[GetPortalCommentsPageByObjectIdResponse(id=2196208, encodeId=33b8219620862, content=1月份投的，马上4月份了，给编辑发了邮件还是没有回审稿意见, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06608356051, createdName=ms4000000341726267, createdTime=Sat Mar 30 11:29:44 CST 2024, time=2024-03-30, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2177807, encodeId=5e5f21e780779, content=投稿发表时间：普遍一审一个月，二审一个月，总历时2-3个月接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54111233, createdTime=Thu Dec 28 15:51:58 CST 2023, time=2023-12-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2179053, encodeId=2d3e21e905393, content=投了一篇，投稿发表流程还是可以的，一审二审基本差不多都是一个月左右的等待，给了一些反馈和建议整个发表过程在2-3个月的时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a7d6407081, createdName=ms358551321, createdTime=Wed Jan 03 15:51:56 CST 2024, time=2024-01-03, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2178721, encodeId=7c9921e8721be, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：该期刊发表的研究可信度和质量都很高，影响因子在过去一年内好像增长了36%，自引率一直比较低4.4%左右，很厉害, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0af16407062, createdName=ms31231444, createdTime=Tue Jan 02 09:41:09 CST 2024, time=2024-01-02, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2176598, encodeId=fbaf21e65988b, content=仔细研究了一下这本期刊，在药学领域的知名度还是很高的，在JCR评估中还获得了Q2的排名。是个潜力骨。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Fri Dec 22 20:24:21 CST 2023, time=2023-12-22, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1113505, encodeId=d3801113505c3, content=两个IF相当的期刊，如何选择要投哪个？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:55 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113506, encodeId=124f111350676, content=选刊时有什么原则吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Tue Dec 28 14:52:55 CST 2021, time=2021-12-28, status=1, ipAttribution=)]

2024-01-02 ms31231444 来自上海

审稿速度:3.0 | 投稿命中率:75.0
经验分享：该期刊发表的研究可信度和质量都很高，影响因子在过去一年内好像增长了36%，自引率一直比较低4.4%左右，很厉害

11 0

[GetPortalCommentsPageByObjectIdResponse(id=2196208, encodeId=33b8219620862, content=1月份投的，马上4月份了，给编辑发了邮件还是没有回审稿意见, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06608356051, createdName=ms4000000341726267, createdTime=Sat Mar 30 11:29:44 CST 2024, time=2024-03-30, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2177807, encodeId=5e5f21e780779, content=投稿发表时间：普遍一审一个月，二审一个月，总历时2-3个月接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54111233, createdTime=Thu Dec 28 15:51:58 CST 2023, time=2023-12-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2179053, encodeId=2d3e21e905393, content=投了一篇，投稿发表流程还是可以的，一审二审基本差不多都是一个月左右的等待，给了一些反馈和建议整个发表过程在2-3个月的时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a7d6407081, createdName=ms358551321, createdTime=Wed Jan 03 15:51:56 CST 2024, time=2024-01-03, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2178721, encodeId=7c9921e8721be, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：该期刊发表的研究可信度和质量都很高，影响因子在过去一年内好像增长了36%，自引率一直比较低4.4%左右，很厉害, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0af16407062, createdName=ms31231444, createdTime=Tue Jan 02 09:41:09 CST 2024, time=2024-01-02, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2176598, encodeId=fbaf21e65988b, content=仔细研究了一下这本期刊，在药学领域的知名度还是很高的，在JCR评估中还获得了Q2的排名。是个潜力骨。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Fri Dec 22 20:24:21 CST 2023, time=2023-12-22, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1113505, encodeId=d3801113505c3, content=两个IF相当的期刊，如何选择要投哪个？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:55 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113506, encodeId=124f111350676, content=选刊时有什么原则吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Tue Dec 28 14:52:55 CST 2021, time=2021-12-28, status=1, ipAttribution=)]

2023-12-22 Gym璨烨来自上海

仔细研究了一下这本期刊，在药学领域的知名度还是很高的，在JCR评估中还获得了Q2的排名。是个潜力骨。

19 0

[GetPortalCommentsPageByObjectIdResponse(id=2196208, encodeId=33b8219620862, content=1月份投的，马上4月份了，给编辑发了邮件还是没有回审稿意见, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06608356051, createdName=ms4000000341726267, createdTime=Sat Mar 30 11:29:44 CST 2024, time=2024-03-30, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2177807, encodeId=5e5f21e780779, content=投稿发表时间：普遍一审一个月，二审一个月，总历时2-3个月接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54111233, createdTime=Thu Dec 28 15:51:58 CST 2023, time=2023-12-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2179053, encodeId=2d3e21e905393, content=投了一篇，投稿发表流程还是可以的，一审二审基本差不多都是一个月左右的等待，给了一些反馈和建议整个发表过程在2-3个月的时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a7d6407081, createdName=ms358551321, createdTime=Wed Jan 03 15:51:56 CST 2024, time=2024-01-03, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2178721, encodeId=7c9921e8721be, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：该期刊发表的研究可信度和质量都很高，影响因子在过去一年内好像增长了36%，自引率一直比较低4.4%左右，很厉害, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0af16407062, createdName=ms31231444, createdTime=Tue Jan 02 09:41:09 CST 2024, time=2024-01-02, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2176598, encodeId=fbaf21e65988b, content=仔细研究了一下这本期刊，在药学领域的知名度还是很高的，在JCR评估中还获得了Q2的排名。是个潜力骨。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Fri Dec 22 20:24:21 CST 2023, time=2023-12-22, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1113505, encodeId=d3801113505c3, content=两个IF相当的期刊，如何选择要投哪个？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:55 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113506, encodeId=124f111350676, content=选刊时有什么原则吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Tue Dec 28 14:52:55 CST 2021, time=2021-12-28, status=1, ipAttribution=)]

2021-12-28 Mia

两个IF相当的期刊，如何选择要投哪个？

34 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2196208, encodeId=33b8219620862, content=1月份投的，马上4月份了，给编辑发了邮件还是没有回审稿意见, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06608356051, createdName=ms4000000341726267, createdTime=Sat Mar 30 11:29:44 CST 2024, time=2024-03-30, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2177807, encodeId=5e5f21e780779, content=投稿发表时间：普遍一审一个月，二审一个月，总历时2-3个月接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54111233, createdTime=Thu Dec 28 15:51:58 CST 2023, time=2023-12-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2179053, encodeId=2d3e21e905393, content=投了一篇，投稿发表流程还是可以的，一审二审基本差不多都是一个月左右的等待，给了一些反馈和建议整个发表过程在2-3个月的时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a7d6407081, createdName=ms358551321, createdTime=Wed Jan 03 15:51:56 CST 2024, time=2024-01-03, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2178721, encodeId=7c9921e8721be, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：该期刊发表的研究可信度和质量都很高，影响因子在过去一年内好像增长了36%，自引率一直比较低4.4%左右，很厉害, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0af16407062, createdName=ms31231444, createdTime=Tue Jan 02 09:41:09 CST 2024, time=2024-01-02, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2176598, encodeId=fbaf21e65988b, content=仔细研究了一下这本期刊，在药学领域的知名度还是很高的，在JCR评估中还获得了Q2的排名。是个潜力骨。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Fri Dec 22 20:24:21 CST 2023, time=2023-12-22, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1113505, encodeId=d3801113505c3, content=两个IF相当的期刊，如何选择要投哪个？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:55 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113506, encodeId=124f111350676, content=选刊时有什么原则吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Tue Dec 28 14:52:55 CST 2021, time=2021-12-28, status=1, ipAttribution=)]

2021-12-28 衣谷

选刊时有什么原则吗？

39 1

展开1条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务